SCHEMBL6310478

SCHEMBL6310478

O=C(Nc1cnccn1)c1c[nH]c2c1-c1nccn1CC2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.38
RAB9A P51151 4/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
ALDH1A1 P00352 1/20 0.37
TSHR P16473 3/20 0.36
NPC1 O15118 2/20 0.36
TP53 P04637 1/20 0.36
MAPT P10636 1/20 0.36
NFKB1 P19838 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36
TRPV4 Q9HBA0 1/20 0.35
KDM4E B2RXH2 2/20 0.34
LMNA P02545 1/20 0.34
SIRT2 Q8IXJ6 1/20 0.33
LRRK2 Q5S007 1/20 0.33
MEN1 O00255 1/20 0.33
CHRNB2 P17787 1/20 0.33
CHRNB4 P30926 1/20 0.33
CHRNA3 P32297 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6302913 0.94 KMT2A (0.36) KMT2ARAB9ASMN1; SMN2ALDH1A1TSHR
SCHEMBL6309523 0.85 MEN1 (0.43) KMT2ARAB9ASMN1; SMN2TSHRNPC1
SCHEMBL6304649 0.83 HTT (0.47) KMT2ASMN1; SMN2ALDH1A1TSHRMAPT
SCHEMBL6305575 0.83 TYK2 (0.40) KMT2AKDM4E
SCHEMBL6302519 0.82 ALDH1A1 (0.32) RAB9AALDH1A1NPC1
SCHEMBL6305551 0.81 CFTR (0.39) KMT2ARAB9ASMN1; SMN2ALDH1A1NPC1
SCHEMBL6308800 0.80 KDM4E (0.42) KMT2ARAB9ASMN1; SMN2ALDH1A1NPC1
SCHEMBL6310006 0.79 RAB9A (0.43) KMT2ARAB9ASMN1; SMN2ALDH1A1NPC1
SCHEMBL6305014 0.78 RAB9A (0.36) KMT2ARAB9ASMN1; SMN2ALDH1A1TSHR
SCHEMBL6309856 0.78 RAB9A (0.36) KMT2ARAB9ASMN1; SMN2ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110778-A1 Heterocyclic compounds as ligands of the GABAA receptor YOHANNES DANIEL (US) 2004-06-10 US claimed
US-20030105081-A1 Heterocyclic compounds as ligands of the GABAA receptor PFIZER INC 2003-06-05 US claimed
US-6949562-B2 Heterocyclic compounds as ligands of the GABAA receptor NEUROGEN CORPORATION (US) 2005-09-27 US disclosed
US-6653471-B2 Tricyclic heteroaromatic compounds containing pyrrole ring; central nervous system disorder treatment; side effect reduction NEUROGEN CORPORATION 2003-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105081-A1 Heterocyclic compounds as ligands of the GABAA receptor GABRB1, GABRP, GABRA1 KMT2A 2120/4885RAB9A 962/4885SMN1; SMN2 3794/4885
US-20040110778-A1 Heterocyclic compounds as ligands of the GABAA receptor GABRB1, GABRP, GABRA1 KMT2A 2120/4885RAB9A 962/4885SMN1; SMN2 3794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.